|
1) Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149: 818-24
|
|
|
|
2) The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342: 1301-8
|
|
|
|
|
3) The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2000; 283: 1995-2002
|
|
|
|
|
|
4) Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004; 351: 327-36
|
|
|
|
|
|
5) Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006; 354: 1671-84
|
|
|
|
|
|
6) Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008; 133: 1120-7
|
|
|
|
|
|
7) Levy MM. PEEP in ARDS─how much is enough？ N Engl J Med. 2004; 351: 389-91
|
|
|
|
|
|
8) Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time？: A systematic review. Am J Respir Crit Care Med. 2009; 179: 220-7
|
|
|
|
|
|
9) Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 2005; 67: 1385-7
|
|
|
|
|
|
10) Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5: 247-64
|
|
|
|
|
|
11) Reutershan J, Vollmer I, Stark S, et al. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2009; 23: 473-82
|
|
|
|
|
|
12) Reutershan J, Cagnina RE, Chang D, et al. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol. 2007; 179: 1254-63
|
|
|
|
|
|
13) Moore CC, Martin EN, Lee GH, et al. An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis. 2008; 8: 141
|
|
|
|
|
|
14) Douillet CD, Robinson WP, 3rd, Zarzaur BL, et al. Mechanical ventilation alters airway nucleotides and purinoceptors in lung and extrapulmonary organs. Am J Respir Cell Mol Biol. 2005; 32: 52-8
|
|
|
|
|
|
15) Eckle T, Fullbier L, Wehrmann M, et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol. 2007; 178: 8127-37
|
|
|
|
|
|
16) Factor P, Mutlu GM, Chen L, et al. Adenosine regulation of alveolar fluid clearance. Proc Natl Acad Sci U S A. 2007; 104: 4083-8
|
|
|
|
|
|
17) Kreindler JL, Shapiro SD. Lung turns to AA (adenosine analogues) to dry out. Nat Med. 2007; 13: 406-8
|
|
|
|
|
|
18) Augustin HG, Koh GY, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009; 10: 165-77
|
|
|
|
|
|
19) Peters KG, Kontos CD, Lin PC, et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res. 2004; 59: 51-71
|
|
|
|
|
|
20) Bouis D, Kusumanto Y, Meijer C, et al. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res. 2006; 53: 89-103
|
|
|
|
|
|
21) Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996; 87: 1171-80
|
|
|
|
|
|
22) Jho D, Mehta D, Ahmmed G, et al. Angio-poietin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca2 influx. Circ Res. 2005; 96: 1282-90
|
|
|
|
|
|
23) Murakami T, Takagi H, Suzuma K, et al. Angiopoietin-1 attenuates H2O2-induced SEK1/JNK phosphorylation through the phosphatidyl-inositol 3-kinase/Akt pathway in vascular endothelial cells. J Biol Chem. 2005; 280: 31841-9
|
|
|
|
|
|
24) Witzenbichler B, Westermann D, Knueppel S, et al. Protective role of angiopoietin-1 in endotoxic shock. Circulation. 2005; 111: 97-105
|
|
|
|
|
|
25) Huang YQ, Sauthoff H, Herscovici P, et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. Crit Care Med. 2008; 36: 262-7
|
|
|
|
|
|
26) Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004; 103: 4150-6
|
|
|
|
|
|
27) Bhandari V, Choo-Wing R, Lee CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med. 2006; 12: 1286-93
|
|
|
|
|
|
28) Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 2006; 3: e46
|
|
|
|
|
|
29) Orfanos SE, Kotanidou A, Glynos C, et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med. 2007; 35: 199-206
|
|
|
|
|
|
30) Gallagher DC, Parikh SM, Balonov K, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock. 2008; 29: 656-61
|
|
|
|
|
|
31) McCarter SD, Mei SH, Lai PF, et al. Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med. 2007; 175: 1014-26
|
|
|
|
|
|
32) Novotny NM, Lahm T, Markel TA, et al. Angiopoietin-1 in the treatment of ischemia and sepsis. Shock. 2009; 31: 335-41
|
|
|
|
|
|
33) Levitt JE, Gould MK, Ware LB, et al. The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med. 2009; 24: 151-67
|
|
|
|
|
|
34) Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993; 147: 218-33
|
|
|
|
|
|
35) Kurahashi K, Kajikawa O, Sawa T, et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest. 1999; 104: 743-50
|
|
|
|
|
|
36) Bitterman PB. Pathogenesis of fibrosis in acute lung injury. Am J Med. 1992; 92: 39S-43S
|
|
|
|
|
|
37) Eisner MD, Parsons P, Matthay MA, et al. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003; 58: 983-8
|
|
|
|
|
|
38) Ishizaka A, Matsuda T, Albertine KH, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004; 286: L1088-94
|
|
|
|
|
|
39) Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006; 173: 1008-15
|
|
|
|
|
|
40) Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax. 2008; 63: 1083-9
|
|
|
|
|
|
41) Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med. 2001; 29: 2325-31
|
|
|
|
|
|
42) Ware LB, Eisner MD, Thompson BT, et al. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004; 170: 766-72
|
|
|
|
|
|
43) Okajima K, Harada N, Sakurai G, et al. Rapid assay for plasma soluble E-selectin predicts the development of acute respiratory distress syndrome in patients with systemic inflammatory response syndrome. Transl Res. 2006; 148: 295-300
|
|
|
|
|
|
44) Sakamaki F, Ishizaka A, Handa M, et al. Soluble form of P-selectin in plasma is elevated in acute lung injury. Am J Respir Crit Care Med. 1995; 151: 1821-6
|
|
|
|
|
|
45) Thickett DR, Armstrong L, Christie SJ, et al. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001; 164: 1601-5
|
|
|
|
|
|
46) Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med. 2002; 166: 1332-7
|
|
|
|
|
|
47) McClintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care. 2008; 12: R41
|
|
|
|
|
|
48) Calfee CS, Eisner MD, Parsons PE, et al. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med. 2009; 35: 248-57
|
|
|
|
|